Clinical Trial: Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression

U.S., Feb. 22 -- ClinicalTrials.gov registry received information related to the study (NCT06839144) titled 'Inhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression' on Feb. 06.

Brief Summary: This study investigates the impact of perioperative inhibition of beta-adrenergic and COX-2 signaling in ovarian cancer patients undergoing debulking surgery. The trial aims to assess the feasibility, safety, and biological effects of a combination of propranolol and etodolac in reducing cancer metastasis and improving immune responses.

Study Start Date: Feb. 28

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer Ovarian Cancer Metastatic Recurrent

Intervention: DRUG: Propranolol (Bet...